Zacks Rating on GlaxoSmithKline PLC (GSK)

GlaxoSmithKline PLC (GSK) : Zacks Investment Research ranks GlaxoSmithKline PLC (GSK) as 3, which is a Hold recommendation. 3 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 3 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 6 research analysts is 2, which indicates as a Buy.

GlaxoSmithKline PLC (GSK) : The highest level GlaxoSmithKline PLC (GSK) is projected to reach is $50 for the short term and the lowest estimate is at $49. The consolidated price target from 2 rating analysts who initiate coverage on the stock is $49.5 and the possibility the share price can swing is $0.71.


Shares of GlaxoSmithKline plc rose by 0.2% in the last five trading days and 1.99% for the last 4 weeks. GlaxoSmithKline plc is up 5.16% in the last 3-month period. Year-to-Date the stock performance stands at 16.37%. GlaxoSmithKline PLC (NYSE:GSK): stock turned positive on Tuesday. Though the stock opened at $44.47, the bulls momentum made the stock top out at $44.5 level for the day. The stock recorded a low of $44.2 and closed the trading day at $44.41, in the green by 0.66%. The total traded volume for the day was 2,490,868. The stock had closed at $44.12 in the previous days trading.

GlaxoSmithKline plc. (GSK) is a healthcare company that researches and develops pharmaceuticals, vaccines and consumer healthcare products. The Company operates in two segments: Pharmaceuticals and Vaccines, and Consumer Healthcare. The Pharmaceuticals segment develops and makes medicines to treat a range of acute and chronic diseases. Its human immunodeficiency virus (HIV) business is managed through ViiV Healthcare. GSKs Vaccines has a portfolio of over 30 paediatric, adolescent, adult travel vaccines. GSKs Established Products Portfolio includes over 50 off-patent products, as well as its branded generics business and other local products. The Consumer Healthcare business develops and markets products in four categories, such as wellness, oral health, nutrition and skin health. Its brands include Sensodyne, Panadol, Horlicks, Polident, Paradontax, Tums, ENO, NiQuitin/Nicorette, Abreva, Zovirax and Aquafresh. It operates in the United Kingdom, the United States, Belgium and China.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.